In the future, it may also be possible to leverage data from whole genome-CRISPR or other functional screens, performed on patient derived material, to identify ALL subtypes potentially responsive to manipulation of the FOXO-PRDM1 axis. Here, PRDM1 is linked to acute lymphoblastic leukemia.